[
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock underperforms Friday when compared to competitors",
    "summary": "Eli Lilly & Co. stock underperforms Friday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=a3887d301d4f1ba9aa24dc1cb5fa060c60ebc74b66451a406419b6588c35fc64",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751041860,
      "headline": "Eli Lilly & Co. stock underperforms Friday when compared to competitors",
      "id": 135654763,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock underperforms Friday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=a3887d301d4f1ba9aa24dc1cb5fa060c60ebc74b66451a406419b6588c35fc64"
    }
  },
  {
    "ts": null,
    "headline": "NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?",
    "summary": "Eli Lilly edges ahead of Novo Nordisk as the stronger obesity bet, backed by robust sales growth, pipeline depth and strategic momentum.",
    "url": "https://finnhub.io/api/news?id=83a9dfcf4baba78030c6c36e02aea81abd8906aa1c2b7aea54680dea42767ae1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751037000,
      "headline": "NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?",
      "id": 135591899,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly edges ahead of Novo Nordisk as the stronger obesity bet, backed by robust sales growth, pipeline depth and strategic momentum.",
      "url": "https://finnhub.io/api/news?id=83a9dfcf4baba78030c6c36e02aea81abd8906aa1c2b7aea54680dea42767ae1"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Looks to Take Share of Booming Obesity Space: Will It Succeed?",
    "summary": "Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.",
    "url": "https://finnhub.io/api/news?id=773e8df99e9f10d590e3ccd24d0d5cac94d2f98a2363ec640dd5a3421d8881c0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751033400,
      "headline": "Amgen Looks to Take Share of Booming Obesity Space: Will It Succeed?",
      "id": 135591900,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.",
      "url": "https://finnhub.io/api/news?id=773e8df99e9f10d590e3ccd24d0d5cac94d2f98a2363ec640dd5a3421d8881c0"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Adds More Than $24B in 6 Months: How to Play ABBV Stock",
    "summary": "ABBV adds $24B in market cap as Skyrizi and Rinvoq drive growth post-Humira, with more upside from a strong pipeline.",
    "url": "https://finnhub.io/api/news?id=baa8826a79472663e04428bdc72eb6478bed7a2639bca8a8adfa9faf0baa12eb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751033280,
      "headline": "AbbVie Adds More Than $24B in 6 Months: How to Play ABBV Stock",
      "id": 135591901,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "ABBV adds $24B in market cap as Skyrizi and Rinvoq drive growth post-Humira, with more upside from a strong pipeline.",
      "url": "https://finnhub.io/api/news?id=baa8826a79472663e04428bdc72eb6478bed7a2639bca8a8adfa9faf0baa12eb"
    }
  },
  {
    "ts": null,
    "headline": "BMO downgrades Verve Therapeutics saying Lilly buyout deal caps upside",
    "summary": "Investing.com -- BMO Capital Markets downgraded Verve Therapeutics to Market perform, saying Eli Lilly’s agreement to buy the gene-editing specialist leaves limited room for the stock to rise before the transaction is expected to close in the third quarter of 2025.",
    "url": "https://finnhub.io/api/news?id=639c5410639c3d6150a6955ca1c349666893774388e3e6c49f5701bc6f91b54c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751032383,
      "headline": "BMO downgrades Verve Therapeutics saying Lilly buyout deal caps upside",
      "id": 135593426,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- BMO Capital Markets downgraded Verve Therapeutics to Market perform, saying Eli Lilly’s agreement to buy the gene-editing specialist leaves limited room for the stock to rise before the transaction is expected to close in the third quarter of 2025.",
      "url": "https://finnhub.io/api/news?id=639c5410639c3d6150a6955ca1c349666893774388e3e6c49f5701bc6f91b54c"
    }
  },
  {
    "ts": null,
    "headline": "Nektar Therapeutics Scores Big Phase 2b Win With Rezpeg",
    "summary": "Nektar Therapeutics Scores Big Phase 2b Win With Rezpeg",
    "url": "https://finnhub.io/api/news?id=0b45b37178cda951e60903f5d5d104055a4845f1df9de875708e814068f04e8f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751013900,
      "headline": "Nektar Therapeutics Scores Big Phase 2b Win With Rezpeg",
      "id": 135590041,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=0b45b37178cda951e60903f5d5d104055a4845f1df9de875708e814068f04e8f"
    }
  }
]